Quarterly Financial Performance: A Stark Contrast
The latest quarter has been challenging for Themis Medicare, with its financial trend shifting from positive to negative. The company’s financial score plummeted to -14 from a positive 9 over the preceding three months, signalling a marked reversal in business momentum. The net profit after tax (PAT) for the quarter stood at a staggering loss of Rs 34.65 crore, representing a dramatic fall of 7,080.2% compared to the average of the previous four quarters. This sharp contraction in profitability is a critical concern for investors and analysts alike.
Operating profit before depreciation, interest and taxes (PBDIT) also recorded a significant loss of Rs 52.42 crore, the lowest in recent history. The operating profit to net sales ratio plunged to -60.28%, underscoring severe margin compression and operational inefficiencies. Furthermore, the company’s operating profit to interest coverage ratio deteriorated to -17.59 times, indicating an inability to comfortably service interest expenses from operating profits.
Liquidity and Working Capital Pressures
Themis Medicare’s liquidity position has weakened considerably. Cash and cash equivalents at the half-year mark dropped to Rs 9.15 crore, the lowest level recorded in recent periods. This decline raises concerns about the company’s ability to meet short-term obligations and fund ongoing operations without resorting to additional financing.
Additionally, the debtor turnover ratio for the half-year fell to 1.92 times, signalling slower collections and potential working capital stress. The company’s interest expenses surged to Rs 2.98 crore in the quarter, the highest recorded, further straining profitability and cash flows.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Stock Price and Market Performance
Themis Medicare’s stock price closed at Rs 104.00 on 14 August 2026, down 3.39% from the previous close of Rs 107.65. The stock’s intraday range was between Rs 102.90 and Rs 116.50, with a 52-week high of Rs 147.99 and a low of Rs 65.00. Despite the recent decline, the stock has delivered a modest year-to-date return of 3.33%, outperforming the Sensex, which is down 8.38% over the same period.
However, the longer-term performance paints a less favourable picture. Over the past three years, Themis Medicare’s stock has declined by 37.05%, contrasting sharply with the Sensex’s 19.53% gain. Similarly, over five years, the stock is down 8.35%, while the benchmark index has surged 40.84%. Even over a decade, the stock’s 102.81% return lags behind the Sensex’s 177.35% appreciation, highlighting persistent underperformance relative to the broader market.
Industry Context and Sectoral Comparison
Operating within the Pharmaceuticals & Biotechnology sector, Themis Medicare faces intense competition and regulatory challenges. The sector has generally exhibited steady growth driven by innovation, increasing healthcare demand, and export opportunities. However, Themis Medicare’s recent financial setbacks and margin contractions suggest it is struggling to capitalise on these sector tailwinds.
Its micro-cap status further exposes it to volatility and liquidity constraints, making it more vulnerable to adverse market conditions and operational disruptions. The downgrade in Mojo Grade from Hold to Sell reflects these risks and the company’s deteriorating fundamentals.
Outlook and Investor Considerations
While the company’s EPS of Rs 2.67 for the quarter is a bright spot, it is overshadowed by the substantial losses in PAT and operating profit. The sharp increase in interest expenses and declining cash reserves raise concerns about financial stability and the ability to sustain operations without restructuring or capital infusion.
Investors should weigh these negative trends against the company’s historical performance and sector dynamics. Themis Medicare’s recent financial deterioration suggests caution, especially given its underwhelming long-term stock returns and micro-cap risks.
Holding Themis Medicare Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: A Cautionary Tale for Investors
Themis Medicare Ltd’s latest quarterly results reveal a company grappling with severe financial and operational challenges. The drastic fall in profitability, margin contraction, and liquidity pressures have culminated in a downgrade to a Sell rating, signalling heightened risk for shareholders.
While the company’s EPS growth offers a glimmer of hope, it is insufficient to offset the broader negative trends. Investors should carefully monitor upcoming quarters for signs of recovery or further deterioration, and consider alternative investments within the Pharmaceuticals & Biotechnology sector that demonstrate stronger financial health and growth prospects.
Given the company’s micro-cap status and recent performance, a cautious approach is warranted until Themis Medicare can demonstrate a sustainable turnaround in its financial trajectory.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
